Prot# WA20495 / ACT3986g: A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to at Least One A

Project: Research project

Project Details

Effective start/end date8/10/078/10/10


  • Quintiles, Inc. (WA20495 / ACT3986g // WA20495 / ACT3986g)
  • Genentech, Inc (WA20495 / ACT3986g // WA20495 / ACT3986g)